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Abstract. This study was performed to evaluate the sen-
sitivity and specificity of technetium-99m methoxyiso-
butylisonitrile (99mTc-MIBI) scintimammography (SMM)
and contrast-enhanced magnetic resonance imaging
(MRI) in patients with breast masses, using the histologi-
cal findings as the gold standard. Forty-five consecutive
patients with a breast lesion, detected by self-examina-
tion, physical examination or screening mammography,
underwent SMM and MRI. In 38 cases (84.5%), the his-
topathology was malignant; the breast cancers ranged
from 3 to 100 mm in diameter (mean 22 mm). In the
overall patient group, MRI showed a slightly higher sen-
sitivity than SMM (92% vs 84%), but SMM showed a
better specificity: 71% vs 42%. The accuracy was 82%
and 84% for SMM and MRI respectively. To evaluate the
influence of lesion size on the results, patients with le-
sions ≤20 mm and ≤15 mm were examined. In patients
with lesions ≤20 mm, the sensitivity of SMM and MRI
decreased to 64% and 82% respectively, while SMM
again displayed considerably better specificity: 83% vs
50% for MRI. The accuracy of SMM and MRI was 64%
and 82% respectively. In patients with lesions ≤15 mm,
SMM again showed better specificity (75% vs 50%),
while MRI displayed better sensitivity and accuracy (sen-
sitivity, 81% vs 62%; accuracy, 75% vs 65%). In this
study the specificity of SMM in patients with breast le-
sions was thus superior to that of MRI. The combination
of SMM and MRI may be used in those patients with
equivocal findings at mammography and ultrasound to
reduce the number of unnecessary surgical biopsies.
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Introduction
Several imaging techniques are used to evaluate breast
cancer in women. Mammography is the most frequently
used screening method, and a decrease in mortality of
33% has been observed for breast cancer in women who
have undergone mammographic screening [1]. Although
mammography is capable of detecting cancer in its early
stages, and has a reasonable cost, it displays low sensi-
tivity and specificity in patients with dense breasts, those
who have previously undergone surgery and those with
breast implants [2, 3, 4].
Since a great number of benign lesions are found in pa-
tients with suspicious mammographic findings, comple-
mentary methods to increase diagnostic specificity have
been proposed. Due to the high spatial resolution of the
most recent ultrasound (US) transducers (7.5–13 MHz)
and the use of echo-enhanced colour power Doppler US,
suspicious areas at mammography can be more accurately
evaluated on US, reducing the number of false positives
[4, 5, 6, 7, 8, 9, 10]. However, variable values for sensitiv-
ity and specificity are still reported in the literature, de-
pending on the anatomical position and dimensions of the
suspicious lesion, on the experience of the physician and
on the quality of the US device [11].
Magnetic resonance imaging (MRI) has been demon-
strated to further improve the sensitivity of mammogra-
phy and US; in fact it gives excellent images of breast
structure and can detect lesions of a few millimetres
[12]. Even though the specificity of MRI is relatively
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low for identifying primary breast cancer, some im-
provement has been achieved by the use of contrast me-
dia (gadolinium-DTPA) [13, 14]. MRI has also been
demonstrated to be useful in the evaluation of axillary
lymph node metastasis [14, 15].
Breast cancer, like other cancers, shows significant
affinity for the radiopharmaceutical technetium-99m me-
thoxyisobutylisonitrile (99mTc-MIBI), with high tumour/
non-tumour ratios [16]. 99mTc-MIBI is a lipophilic agent
and furthermore is a substrate of P-glycoprotein (Pgp),
which is considered one of the multi-drug resistance
(MDR) agents [17]. Scintimammography (SMM) has
been demonstrated to be useful in the diagnosis of pri-
mary breast tumours in patients with dense breasts [18],
and its value has especially been emphasised in the eval-
uation of therapy response [19, 20]. Moreover, SMM
may be considered a non-invasive method for the identi-
fication of MDR-positive patients, assisting in the choice
of the most suitable therapy [19, 20, 21]. Our study goal
was to evaluate the sensitivity and specificity of SMM
and MRI, using the histological findings as the gold
standard.
Materials and methods
Patient population. We examined 45 consecutive patients (age
range 32–84 years, mean 51 years) with a suspicious breast lesion
detected by self-examination, physical examination or screening
mammography. Afterwards all the patients underwent US. Mam-
mography and US were performed according to standard proce-
dures. The patients underwent MRI and SMM prior to fine-needle
aspiration biopsy (FNAB). The patients with breast cancer at
FNAB underwent surgery, and malignancies were classified by the
pathologist according to WHO nomenclature and staged as fol-
lows: pT1is (carcinoma in situ), pT1a (1–5 mm in largest diame-
ter), pT1b (6–10 mm), pT1c (11–20 mm), pT2 (21–50 mm) or pT3
(>51 mm without involvement of the chest wall or the skin). The
size of benign lesions was determined by US.
Magnetic resonance imaging. MRI was obtained with a General
Electric device at 1.5 Tesla using a dedicated breast coil, enabling
the simultaneous imaging of both breasts with the patient in the
prone position. The data acquisition was performed directly before
and after i.v. injection of gadolinium-DTPA using appropriate 3D
gradient and spin echo sequences with fat tissue subtraction;
20–50 continuous transverse slices were obtained. The qualitative
and quantitative analysis of gadolinium-DTPA enhancement was
performed using regions of interest and flow curves. Lesions with
marked, rapid enhancement and the washout sign and those with
inhomogeneous or rim enhancement and irregular outlines were
classified as malignant or probably malignant and interpreted as
positive. MRI images were considered true positive when the ma-
lignant or probably malignant lesion was confirmed by histopa-
thology. MRI was interpreted as true negative when the images
and histopathology excluded breast cancer.
Scintimammography. SMM was performed with a Picker Axis du-
al-headed gamma camera, equipped with a parallel-hole, low-en-
ergy, high-resolution collimator. The test was performed using the
standard technique: 740 MBq 99mTc-MIBI was injected i.v. in the
opposite arm to the breast with the suspected lesion. In all pa-
tients, planar imaging was performed using a 256×256 matrix with
an acquisition time of 10–15 min, in both lateral and anterior
views, at 20–30 min after injection. Patients were examined in the
prone position using an imaging table with breast “cut-outs”. To
avoid interference from the opposite breast, a layer of lead was
used as a shield. The SMM images were classified based on visual
interpretation. Focal tracer accumulation in the breast was inter-
preted as suspicious or probably malignant and such scintigrams
were classified as positive. The suspicious or probably malignant
images were considered true positive when confirmed by histopa-
thology. The SMM was interpreted as true negative when the im-
ages and histopathology excluded breast cancer.
Image interpretation. The MR and SMM images were interpreted
separately by three expert radiologists and three expert nuclear
medicine physicians who worked independently. They were blind-
ed to the results of MRI or SMM.
Results
The lesion size in the entire patient group ranged from 3
to 100 mm, with a mean of 22 mm. In 7 of 45 cases
(15.5%), the histopathology was benign, revealing hy-
perplasia (two patients), sclerosing adenosis (two pa-
tients), granuloma (one patient), fibroadenoma (one pa-
Table 1. Results of SSM and MRI in patients with benign disease
Patients Age (years) Histopathology Size (mm) SSM MRI
TP TN FP FN TP TN FP FN
1 33 Granuloma 15 + +
2 48 Hyperplasia 13 + +
3 46 Fibroadenoma 10 + +
4 55 Hyperplasia 15 + +
5 84 Breast involution 16 + +
6 70 SC-AD 25 + +
7 72 SC-AD 10 + +
Overall 5 2 3 4
SC-AD, Sclerosing adenosis; TP, true positive; TN, true negative; FP, false positive; FN, false negative
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Table 2. Results of SSM and MRI in patients with breast cancer
Patients Age (years) Histopathology Staging SSM MRI
(pT)
TP TN FP FN TP TN FP FN
1 37 DC pT2 + +
2 39 DC pT3 + +
3 49 DC pT3 + +
4 65 N pT1a + +
5 60 DC pT2 + +
6 56 DC pT2 + +
7 47 DC pT2 + +
8 45 DC pT2 + +
9 54 DC pTis + + 
10 50 DC pT2 + +
11 56 DC pT2 + +
12 45 DC pT2 + +
13 67 DC pT3 + +
14 43 LC pT2 + +
15 56 LC pT1c + +
16 66 DC pT2 + +
17 38 DC pT1c + +
18 58 DC pT1b + +
19 48 DC pT1c + +
20 65 LC pT1a + +
21 43 DC pT1c + +
22 70 DC pT1c + +
23 40 DC pT2 + +
24 37 DC pT2 + +
25 37 DC pTis + +
26 36 DC pT2 + +
27 59 DC pT1c + +
28 64 DC pT1c + +
29 43 DC pT2 + +
30 46 LC pT1b + +
31 45 DC pT2 + +
32 48 DC pT1b + +
33 47 DC pT2 + +
34 61 DC pT2 + +
35 65 DC pT1c + +
36 41 DC pT1c + +
37 47 DC pT1c + +
38 38 DC pT2 + +
Overall 32 6 35 3
TP, True positive; TN, true negative; FP, false positive; FN, false negative; DC, ductal carcinoma; LC, lobular carcinoma; N, neuroendo-
crine carcinoma
tient) or breast involution (one patient) (Table 1). The
size of these lesions ranged from 10 to 25 mm (mean
22 mm).
The malignant lesions (84.5% of patients) had a di-
ameter of 3–100 mm (mean 23 mm) and included 33
ductal carcinomas, four lobular carcinomas and one
case of neuroendocrine carcinoma (Table 2). Of these
lesions, 5.3% were classified as pT1is, 5.3% as pT1a,
7.9% as pT1b, 26.3% as pT1c, 47.3% as pT2 and 7.9%
as pT3.
SMM was true positive in 32 lesions and false nega-
tive in six (two ductal carcinomas in situ and four carci-
nomas up to 10 mm: two ductal carcinomas, one lobular
carcinoma and one neuroendocrine carcinoma). MRI ap-
peared true positive in 35 breast cancer and false nega-
tive in three (one ductal carcinoma in situ and two carci-
nomas up to 8 mm: a neuroendocrine carcinoma and a
ductal carcinoma).
SMM was false positive in a patient with breast invo-
lution and in a case of sclerosing adenosis. MRI ap-
peared false positive in four patients: two with hyperpla-
sia and two with sclerosing adenosis.
The value of SMM and MRI as diagnostic tests is
shown in Table 3. In our population of patients, MRI
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showed a slightly better sensitivity than SMM (92% vs
84%) whereas SMM displayed a clearly higher specifici-
ty: 71% vs 42%. The positive predictive value was simi-
lar for SMM and MRI (94% vs 89% respectively), as
was the negative predictive value (45% vs 50% respec-
tively). We found an accuracy of 82% and 84% for SMM
and MRI respectively.
To evaluate the influence of lesion size on our results,
we examined patients with lesions ≤20 mm and with le-
sions ≤15 mm (Table 4). In the subgroup of patients with
lesions ≤20 mm, the sensitivity of SMM and MRI de-
creased to 64% and 82% respectively, while SMM again
displayed considerably better specificity: 83% vs 50%
for MRI. The positive and negative predictive values of
SMM and MRI remained practically unchanged com-
pared with the overall patient group. The accuracy of
SMM and MRI was 64% and 82% respectively.
In the subgroup of patients with lesions ≤15 mm,
SMM continued to show better specificity (75% vs
50%), while MRI again displayed higher sensitivity and
accuracy (sensitivity, 81% vs 62%; accuracy, 75% vs
65%). The positive and negative predictive values were
90% and 33% for SMM, and 86% and 40% for MRI re-
spectively.
Discussion
Mammographic screening programmes have proved use-
ful for the early detection of breast cancer but, as already
mentioned, the sensitivity and specificity of mammogra-
phy are reduced in dense glandular breasts, in patients
who have previously undergone surgery and in those
with breast implants. Consequently a large number of
excisional biopsies are performed in such patients [2, 3,
4]. To improve the diagnostic outcome of mammogra-
phy, US and echo-enhanced colour Doppler have been
employed as a complementary tool and indeed reduce
the number of false positives. For instance, US has
proved useful in patients with dense breasts, breasts with
architectural distortion, or breasts with suspicious spicu-
late lesions, as well as in differentiating cysts from solid
masses [4].
Among the additional techniques used to improve the
sensitivity and the specificity in identifying breast can-
cer, MRI and SMM have yielded good results. MRI has
shown high sensitivity in the detection of breast cancer
(a few millimetres in thickness) thanks to the develop-
ment of high-resolution surface coils, fast imaging se-
quences, fat suppression and the use of gadolinium-
DTPA. However, MRI has a low specificity, since some
carcinomas behave atypically, enhancing only slightly
and gradually (lobular carcinoma) or being well defined
(papillary and mucinous carcinomas). Ductal carcinoma
and ductal carcinoma in situ have a variable appearance
on MRI, depending on the neoangiogenesis, and it is not
possible to differentiate inflammatory carcinoma from
other benign causes of inflammation [22]. In addition,
some benign lesions display enhancement after gadolini-
um-DTPA, e.g. fibroadenomas [22].
For about a decade, SMM has been a promising tech-
nique for the imaging of breast cancer, though unfortu-
nately its specificity and sensitivity have depended on le-
sion size (with low sensitivity and high specificity in
small lesions). Various published studies have compared
SMM and MRI. Palmedo et al. [23], in a group of 56 pa-
tients, reported an overall sensitivity and specificity of
93% and 21% respectively for MRI, while the sensitivity
and specificity of SMM were 85% and 66% respectively.
Tiling et al. [24] performed SMM and MRI in 82 pa-
tients with indeterminate mammograms. When indeter-
minate findings were included in the group of positive
diagnoses, the sensitivity and specificity of SMM were
79% and 70%, and those of MRI 84% and 49% respec-
tively. When indeterminate results were considered neg-
ative, SMM showed a sensitivity and specificity of 62%
and 83%, while the sensitivity and specificity of MRI
were 56% and 79%, respectively. In a group of 49 pa-
tients with equivocal mammographic findings, Imbriaco
et al. [25] reported a sensitivity of 80% and a specificity
Table 3. Sensitivity, specificity,
positive predictive value, nega-
tive predictive value and accu-
racy of SSM and MRI in the
overall patient group
Sensitivity Specificity PPV NPV Accuracy
SSM 84 71 94 45 82
MRI 92 42 89 50 84
PPV, Positive predictive value; NPV, negative predictive value
Table 4. Sensitivity, specifici-
ty, positive predictive value,
negative predictive value and
accuracy in lesions ≤20 mm
and ≤15 mm
Sensitivity Specificity PPV NPV Accuracy
Size (mm) ≤20 ≤15 ≤20 ≤15 ≤20 ≤15 ≤20 ≤15 ≤20 ≤15
SSM 64 62 83 75 91 90 45 33 64 65
MRI 82 81 50 50 82 86 50 40 82 75
PPV, Positive predictive value; NPV, negative predictive value
of 88% for SMM, as compared with figures of 96% and
75%, respectively, for MRI.
In our patients, in accordance with previous studies,
SMM showed a higher overall specificity in comparison
with MRI (71% vs 42%). This was probably due to the
presence of benign lesions which enhanced after gado-
linium-DTPA, a likely expression of a high degree of
neovascularity; by contrast, 99mTc-MIBI uptake depends
on the metabolic activity of the cells (mitochondrial con-
centration in the cells).
As shown previously, MRI displayed a higher sensi-
tivity than SMM (92% vs 84%). In particular, the two
ductal carcinomas in situ and the neuroendocrine carci-
noma were below the intrinsic spatial resolution of the
gamma camera detector. For the smaller lesions
(≤15 mm), the sensitivity and specificity of SMM were
62% and 75%, as compared with 75% and 50% for MRI.
These values are slightly lower than those reported by
Imbriaco et al. [25], who found the sensitivity and speci-
ficity of SMM to be 77% and 88% in patients with le-
sions ≤15 mm, as compared with 100% and 75%, respec-
tively, for MRI. Our data were similar to those reported
by Palmedo et al. [23], who found that for non-palpable
lesions, SMM showed lower sensitivity than MRI (60%
vs 100%) (two of four missed carcinomas were <8 mm)
but higher specificity (75% vs 50%).
The three lesions larger than 15 mm that were never-
theless false negative on SMM (two ductal carcinomas
and one lobular carcinoma) were sited at the inner quad-
rants of the breast (where scatter radiation from the liver
and the myocardium may have an effect) or near the
chest wall. Improvement in the sensitivity of SMM for
the detection of such lesions will occur with the develop-
ment of a high-resolution, small-field-of-view breast-
specific gamma camera, as demonstrated by the prelimi-
nary results using a prototype gamma camera [26].
We found the overall diagnostic accuracy of SMM
and MRI to be 82% and 84% respectively; these are sim-
ilar to the values reported by Imbriaco et al. [25]. The
accuracy was lower for smaller lesions, and this was
more evident for SMM (65%) than for MRI (75%). The
overall positive predictive value was also similar be-
tween SMM and MRI (94% and 89%, respectively), and
lesion size did not significantly affect this value (in le-
sions ≤15 mm the positive predictive value was 90% for
SMM and 86% for MRI).
We conclude that in this study the specificity of SMM
in patients with breast lesions was superior to that of
MRI. Unfortunately, the sensitivity of SMM is still un-
satisfactory owing to the intrinsic spatial resolution of
gamma camera detector and high variability in the up-
take of 99mTc-MIBI. Given the simplicity of the proce-
dure and the lower costs, SMM may be preferred to MRI
in the evaluation of equivocal breast lesions larger than
10 mm and of lesions in dense glandular breasts. MRI is
to be preferred in clinical practice if high spatial resolu-
tion is needed; moreover, MRI can be recommended in
the local staging of breast cancer for the planning of sur-
gery. On the basis of the obtained results, however, it is
doubtful whether these expensive and time-consuming
imaging techniques can be applied in daily routine in pa-
tients in whom biopsy allows easy and inexpensive eval-
uation.
Even though the low negative predictive value of
SMM and MRI leads surgeons to continue to perform bi-
opsies of equivocal breast lesions, thereby minimising
the number of missed carcinomas, the combination of
SMM and MRI may be proposed as a second-line ap-
proach in those patients in whom mammography and US
are non-diagnostic or difficult to interpret, e.g. those
with very dense breasts, mammographically occult tu-
mours, suspected multifocality or multicentricity, or sus-
pected chest wall involvement. In these situations, SMM
and MRI can help by guiding the biopsy to assure that
the samples are taken from the correct site.
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